SpyGlass Pharma ratios data for the quarter ended Jun 2026. These financial ratios cover 1 quarter of results, standardized by Business Quant from the company’s SEC filings.
| Ratios | Jun2026 |
|---|---|
| Efficiency | |
| Assets AverageAssets Avg. | 179.65M |
| Valuation | |
| Price to EarningsP/E | -37.48 |
| Price to BookP/B | 3.20 |
| Enterprise Value | 510.33M |
| EV to EBIT | -23.23 |
| EV to EBITDA | -23.23 |
| Market Capitalization | 744.51M |